Med. Pro Praxi 2006; 2: 58-61

Kardiovaskulární prevence

MUDr. Michal Vrablík Ph.D
III. interní klinika VFN a 1. LF UK, Praha

Kardiovaskulární prevence stále neztrácí na aktuálnosti. Kumulace výsledků klinických studií dala podnět k formulaci nových odborných doporučení pro prevenci kardiovaskulárních onemocnění. Rozšířilo se spektrum nemocných, které považujeme za vysoce rizikové, změnil se systém určování rizika, byly určeny nové cílové hodnoty rizikových faktorů. Důraz je kladen na komplexní intervenci všech přítomných rizik s využitím všech farmakologických i nefarmakologických prostředků. Článek komentuje některé aspekty kardiovaskulární prevence z praktického hlediska.

Keywords: kardiovaskulární onemocnění, hypolipidemika, metabolický syndrom, cílové hodnoty

Published: September 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vrablík M. Kardiovaskulární prevence. Med. praxi. 2006;3(2):58-61.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alberti KGMM, Zimmet P, Shaw J. The metabolic syndrome - new worlwide definition. Lancet 2005; 366: 1059-1062. Go to original source... Go to PubMed...
    2. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504. Go to original source... Go to PubMed...
    3. Cífková R a členové společné pracovní skupiny. Prevence kardiovaskulárních onemocnění v dospělém věku. Cor Vasa 2005; 47: 3-14.
    4. Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML; EUROPA Investigators. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005; 26: 1369-1378. Go to original source... Go to PubMed...
    5. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10: S1-S10. Go to original source... Go to PubMed...
    6. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788. Go to original source... Go to PubMed...
    7. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 2004; 24: e149-161. Go to original source... Go to PubMed...
    8. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005; 48:1648-1699. Go to original source... Go to PubMed...
    9. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, aakso M. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861. Go to original source... Go to PubMed...
    10. Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, Andres R, Saudek C, Edelstein SL, Arakaki R, Murphy MB, Shamoon H; The Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 2005; 54: 2404-2414. Go to original source... Go to PubMed...
    11. Lip GY, Beevers DG. More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPE-TOO and SYST-EUR2). J Hum Hypertens 2003; 17: 747-750. Go to original source... Go to PubMed...
    12. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Lancet 1990; 335: 765-774. Go to original source... Go to PubMed...
    13. Muhlestin JB. Post-hospitalization management of high-risk coronary patients. Am J Cardiol. 2000; 85: 13B-20B. Go to original source... Go to PubMed...
    14. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, et al; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-1080. Go to original source... Go to PubMed...
    15. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB; VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001; 285: 1585-1591. Go to original source... Go to PubMed...
    16. Stergiou GS, Salgami EV. World Health Organization-International Societ of Hypertension (WHO-ISH); USA Joint National Committee on Prevention, Detection, Evalutiaon, and Treatment of High Blood Pressure (JNC-7); European Soceity of Hypertension-European Society of Cardiology (ESH-ESC). New European, American and International guidelines for hypertension management: agreement and disagreement. Expert Rev Cardiovasc Ther 2004; 2: 359-368. Go to original source... Go to PubMed...
    17. Špinar J, Hradec J, Málek I, Toman J. Doporučení pro diagnostiku a léčbu chronického srdečního selhání. Cor Vasa 2001; 43: K123-K137.
    18. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419-1424. Go to original source... Go to PubMed...
    19. Zdravotnická ročenka České republiky za rok 2004. ÚZIS Praha, 2005: 270.
    20. Zimmet PZ, Alberti G. The metabolic syndrome: perhaps an ethiologic mystery but far from a myth. Where doues the International diabetes federation stand? Medscape Diabetes and Endocrinology 2005; 7(2), www.Medscape.com.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.